Your session is about to expire
← Back to Search
Oxygen Therapy
Nocturnal Oxygen Needs and Central Sleep Apnea in Patients With Chronic Heart Failure. (HO2F Trial)
Phase 4
Waitlist Available
Research Sponsored by Laval University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up three months ( titration completed 3 times during the study period)
Awards & highlights
Drug Has Already Been Approved
No Placebo-Only Group
Pivotal Trial
Summary
This trial is testing different levels of oxygen flow during sleep in order to minimize oxygen desaturation while also minimizing periods of hyperoxia.
Eligible Conditions
- Chronic Heart Failure
- Central Sleep Apnea
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ three months ( titration completed 3 times during the study period)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~three months ( titration completed 3 times during the study period)
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Accuracy of automated oxygen titration
Changes in optimal levels of O2 flow ( EO2F) which prevent nocturnal O2 desaturation
Awards & Highlights
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Oxygen therapyExperimental Treatment1 Intervention
Fixed nightime oxygen therapy throughout the protocol duration
Find a Location
Who is running the clinical trial?
Laval UniversityLead Sponsor
434 Previous Clinical Trials
178,527 Total Patients Enrolled
OxynovUNKNOWN
Philips RespironicsIndustry Sponsor
67 Previous Clinical Trials
9,674 Total Patients Enrolled